Published on
Aug 27, 2026
Right goal, wrong strategy: Why Trump’s ‘Made in America’ plan leaves us vulnerable
A generic drug finished in an American factory but dependent on a single overseas supplier for its active ingredient may be less secure than an imported medicine produced at two independent plants with multiple qualified suppliers.That distinction matters …
Source:
Washington Examiner
-
Right-wing
